Britain and America have secured a important bilateral deal that will preserve zero levies on British drug shipments being sold in the US market.
The Terms of the Accord
As part of the deal, the UK has committed to boost spending on medicines through the National Health Service (NHS). This move secures that import taxes on these key goods will remain at zero for a timeframe of 36 months.
This agreement comes after recent statements to significantly raise tariffs on branded drug imports, with increases mentioned up to one hundred percent.
"This arrangement between the UK strengthens the global environment for innovative medicines and introduces much-needed equity to U.S.–U.K. drug exports," a release said.
Economic Importance
Drugs represent one of the the United Kingdom's largest exports to the America, which is easily the primary buyer for large companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months prior to last September, the UK sold drugs totaling billions to the US. This figure represented 17.4% of all goods exports in that period.
"This agreement secures work, boosts capital expenditure and facilitates the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Detailed NHS Changes
The agreement involves several notable commitments from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to double total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The amount manufacturers must return to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates topped 20%.
Broader Context
This agreement follows a long-running dispute between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
The disagreement were exacerbated by assertions that American patients were charged a premium for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while major funding commitments have been pledged toward projects in the United States.
The Science Minister stated that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a share of its overall budget over the previous ten-year period.
